Modified bismuth quadruple therapy with low dose metronidazole as first-line therapy for Helicobacter pylori infection

被引：0
|
作者：
Pih, G. [1 ]
Choi, K. [1 ]
Na, H. [1 ]
Ahn, J. [1 ]
Lee, J. [1 ]
Jung, K. [1 ]
Kim, D. [1 ]
Song, H. [1 ]
Lee, G. [1 ]
Jung, H. [1 ]
机构：
[1] Asan Med Ctr, Seoul, South Korea
来源：
HELICOBACTER | 2020年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
EP2.42
引用
收藏
页码：44 / 44
页数：1
相关论文
共 50 条
  • [21] Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection
    Boixeda, D
    Bermejo, F
    Martín-De-Argila, C
    López-Sanromán, A
    Defarges, V
    Hernández-Ranz, F
    Milicua, JM
    García-Plaza, A
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (08) : 1457 - 1460
  • [22] Metronidazole quadruple therapy for infection with metronidazole resistant Helicobacter pylori:: A prospective study
    Graham, DY
    Osato, MS
    Hoffman, J
    Opekun, AR
    Anderson, SY
    El-Zimaity, HMT
    [J]. GUT, 1999, 45 : A120 - A120
  • [23] Moxifloxacin Containing Triple Therapy vs. Moxifloxacin and Bismuth-Containing Quadruple Therapy for First-Line Treatment of Helicobacter pylori (H. pylori) Infection
    Ciccaglione, Antonio Francesco
    Cellini, Luigina
    Grossi, Laurino
    Di Tullio, Ada Maria
    Pagliaro, Mauro
    Tavani, Roberta
    Cocciolillo, Sila
    Marzio, Leonardo
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S482 - S482
  • [24] What is the best first-line therapy for Helicobacter pylori infection?
    Xavier Calvet
    [J]. Nature Clinical Practice Gastroenterology & Hepatology, 2008, 5 : 606 - 607
  • [25] What is the best first-line therapy for Helicobacter pylori infection?
    Calvet, Xavier
    [J]. NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2008, 5 (11): : 606 - 607
  • [26] Comparison of the traditional triple and a new bismuth-containing quadruple therapy in the first-line eradication of Helicobacter pylori
    Varga Mate
    Dracz Lajos
    Kolbenheyer Erik
    Varga Ferenc
    Patai Arpad, V
    Solymosi Norbert
    Patai Arpad
    [J]. ORVOSI HETILAP, 2019, 160 (34) : 1340 - 1345
  • [27] Bismuth-Based Quadruple Therapy versus Metronidazole- Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant Helicobacter pylori Infection: A Multicenter Randomized Controlled Trial
    Seo, Seung In
    Lim, Hyun
    Bang, Chang Seok
    Yang, Young Joo
    Baik, Gwang Ho
    Lee, Sang Pyo
    Jang, Hyun Joo
    Kae, Sea Hyub
    Kim, Jinseob
    Kim, Hak Yang
    Shin, Woon Geon
    [J]. GUT AND LIVER, 2022, 16 (05) : 697 - 705
  • [28] Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial
    Lim, Hyun
    Bang, Chang Seok
    Shin, Woon Geon
    Choi, Jae Ho
    Soh, Jae Seung
    Kang, Ho Suk
    Yang, Young Joo
    Hong, Ji Taek
    Shin, Suk Pyo
    Suk, Ki Tae
    Lee, Jae Jun
    Baik, Gwang Ho
    Kim, Dong Joon
    [J]. MEDICINE, 2018, 97 (46)
  • [29] Independent risk factors predicting eradication failure of standard bismuth quadruple therapy for the first-line treatment of Helicobacter pylori infection in Taiwan
    Shie, Chang-Bih
    Tsay, Feng-Woei
    Wu, Deng-Chyang
    Kao, Sung-Shuo
    Chen, Yan-Hua
    Tsai, Kun-Feng
    Huang, Wen-Wei
    Tang, Sheng-Yeh
    Kuo, Li-Fu
    Wu, I-Ting
    Hsu, Ping-, I
    [J]. ADVANCES IN DIGESTIVE MEDICINE, 2024,
  • [30] Vonoprazan Dual or Triple Therapy Versus Bismuth-Quadruple Therapy as First-Line Therapy for Helicobacter pylori Infection: A Three-Arm, Randomized Clinical Trial
    Cheung, Ka Shing
    Lyu, Tao
    Deng, Zijie
    Han, Shaowei
    Ni, Li
    Wu, Juan
    Tan, Jing Tong
    Qin, Jian
    Ng, Ho Yu
    Leung, Wai K.
    Seto, Wai-Kay
    [J]. HELICOBACTER, 2024, 29 (05)
12345